Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer

BACKGROUND: Front-line maintenance therapy with bevacizumab demonstrates high efficacy and safety in epithelial ovarian cancer, as already shown in large phase III trials; however, the corresponding study populations are often not fully representative of patients in clinical routine. In this Austria...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsibulak, Irina, Polterauer, Stephan, Reinthaller, Alexander, Schauer, Christian, Berger, Jürg, Marth, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606045/
https://www.ncbi.nlm.nih.gov/pubmed/35146539
http://dx.doi.org/10.1007/s00508-022-02005-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606045/
https://www.ncbi.nlm.nih.gov/pubmed/35146539
http://dx.doi.org/10.1007/s00508-022-02005-2

Ejemplares similares